Journal
NATURE CHEMICAL BIOLOGY
Volume 8, Issue 4, Pages 393-399Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.797
Keywords
-
Categories
Funding
- Scottish Rite Charitable Foundation
- Canadian Institutes of Health Research (CIHR)
- Alzheimer Society of Canada
- Canada Research Chairs program
- Michael Smith Foundation for Health Research (MSFHR)
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Human Frontier Science Program
Ask authors/readers for more resources
Oligomerization of tau is a key process contributing to the progressive death of neurons in Alzheimer's disease. Tau is modified by O-linked N-acetylglucosamine (O-GlcNAc), and O-GlcNAc can influence tau phosphorylation in certain cases. We therefore speculated that increasing tau O-GlcNAc could be a strategy to hinder pathological tau-induced neurodegeneration. Here we found that treatment of hemizygous JNPL3 tau transgenic mice with an O-GlcNAcase inhibitor increased tau O-GlcNAc, hindered formation of tau aggregates and decreased neuronal cell loss. Notably, increases in tau O-GlcNAc did not alter tau phosphorylation in vivo. Using in vitro biochemical aggregation studies, we found that O-GlcNAc modification, on its own, hinders tau oligomerization. O-GlcNAc also inhibits thermally induced aggregation of an unrelated protein, TAK-1 binding protein, suggesting that a basic biochemical function of O-GlcNAc may be to prevent protein aggregation. These results also suggest O-GlcNAcase as a potential therapeutic target that could hinder progression of Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available